On December 4, Kazakhstan’s Minister of Health Alexei Choi and the President of the Russian Direct Investment Fund Dmitriev signed an agreement on cooperation in the field of accelerated registration, production and dissemination of the “Satellite-V” COVID-19 vaccine.
According to the agreement, after the relevant departments of Kazakhstan carry out the necessary procedures, the Russian side will transfer technology and provide Kazakhstan with raw materials for the production of not less than 2 million doses of vaccines.
Alexei Choi said that the heads of state of Kazakhstan and Russia have reached a consensus on the production of a “satellite-V” coronavirus vaccine in Kazakhstan, which will help promote bilateral cooperation and create conditions for defeating the novel coronavirus this morning.
Dmitriev said that Kazakhstan will receive more than 90% of the effective coronavirus vaccines, and the production of vaccines in Kazakhstan will reduce transportation expenses and help provide vaccines to medical institutions as soon as possible.
This also helps to deepen the exchange of experience in the field of science, technology and medicine between the two countries.
According to reports, the Russian Ministry of Health registered the world’s first COVID-19 vaccine, Satellite-V, in August. The vaccine was jointly developed by the National Center for Epidemiology and Microbiology of Gamalea and the Russian Direct Investment Fund.
It adopts a two dose inoculation procedure, with two human adenoviruses as vectors, and the vaccination interval is three weeks.” Phase III clinical trials of satellite-V are being carried out in Russia, Belarus, the United Arab Emirates, India and Brazil.
The Russian Direct Investment Fund said that it had received applications from more than 50 countries to buy more than 1.2 billion doses of “satellite-V” vaccine.
Vaccines supplied to foreign markets will be produced by international partners of Russian Direct Investment Fund in India, Brazil, China, South Korea and other countries.
The first phase of the “Satellite-V” vaccine trial in phase III clinical trials showed that the vaccine was 92% effective, and the volunteers who were vaccinated did not have serious side effects.